BackCalidi Biotherapeutics Overview

Calidi Biotherapeutics Other Current Liabilities

Track Calidi Biotherapeutics's other current liabilities ($1.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.13M
↓ 41.52% YoYΔ $-803000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Calidi Biotherapeutics Other Current Liabilities History

Loading

Calidi Biotherapeutics vs. peers: Other Current Liabilities Comparison

Loading

Calidi Biotherapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Calidi Biotherapeutics (CLDI) FAQ

As of the most recent data (June 2026), CLDI shows a other current liabilities of $1.1M. That compares with $1.9M in the prior-year period — down 41.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CLDI's other current liabilities is now $1.1M (was $1.9M) — a 41.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Calidi Biotherapeutics is outperforming or lagging.

Tracking CLDI's other current liabilities over time shows whether Calidi Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1M That compares with $1.9M in the prior-year period — down 41.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Calidi Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.1M) with ownership activity and broader fundamentals.